Latest news

Search
Categories
News archive

Nanologica Interim Report Jan – Sep 2021

29 October, 2021

FINANCIAL SUMMARY Net sales for the third quarter amounted to TSEK 2,119 (2,089) and for the nine-month period to TSEK 12,238 (10,064) The operating result for the quarter amounted to TSEK -11,718 (-5,795) and for the nine-month period to TSEK -26,581 (-15,924) Result after tax for the quarter amounted to TSEK -12,546 (-5,899) and for the nine-month period to TSEK -29,607 (-16,772) Earnings per share before and after dilution were SEK -0.45 (-0.21) for the

Read more »

CEO comment third quarter 2021

29 October, 2021

FOCUS ON PRODUCTION! Net sales for the quarter increased marginally to TSEK 2,119, most of which again is derived from our partner project with Vicore Pharma. The quarter’s increased operating loss compared to the previous year is according to plan and is mainly due to the expansion phase in which the company is currently in. To take the next step in our growth, we are now fully focused on completing large-scale production capacity, which is

Read more »

Nanologica to Exhibit on BCEIA

17 September, 2021

Nanologica will exhibit on BCEIA (Beijing Conference and Exhibition an Instrumental Analysis) held in Beijing Sep 27-29. BCEIA is a world exposition on analytical science and biochemical technology that attracted more than 25,000 registered participants in 2017.

Read more »

Nanologica Closes NIC-001

17 September, 2021

Nanologica AB has decided to close the project with the drug candidate NIC-001 for the treatment of gastroparesis before the planned clinical study begins, in order to focus the company’s resources on the continued development of the inhalation platform NLAB Spiro®. The closure of the project is a result of the company’s strategy in the drug development business area being refined to focus on inhalation and respiratory diseases, and because the commercial conditions for NIC-001

Read more »

Nanologica avslutar NIC-001

17 September, 2021

Nanologica AB har beslutat att avsluta sitt projekt med läkemedelskandidaten NIC-001 för behandling av gastropares innan den planerade kliniska studien påbörjas, för att fokusera bolagets resurser på fortsatt utveckling av inhalationsplattformen NLAB Spiro®. Stängningen av projektet är en följd av att bolagets strategi inom affärsområdet drug development framgent fokuseras på inhalation och respiratoriska sjukdomar, samt av att de kommersiella förutsättningarna för NIC-001 har förändrats. I och med att projektet avslutas överförs interna resurser till inhalationsprojekt

Read more »